ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017
Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 84 citations in OpenAlex.
- A case-control study of blood group antigen expression in Babesia microti infected patients in the United States.Transfusion · 2026Article
- Cross-species therapeutics in Plasmodium and Babesia: erythrocyte invasion and conserved drug targets.Tropical animal health and production · 2026Review
- Evaluating acridones as novel therapeutics for human babesiosis.Antimicrobial agents and chemotherapy · 2026Article
- Tafenoquine: A Breakthrough Option for Babesiosis Treatment.Tropical medicine and infectious disease · 2026Article
- Article
- A Rare Presentation of Babesia-Associated Splenic Infarction in an Immunocompetent Young Male With Mild Parasitemia.Case reports in medicine · 2026Article
- Natural products against Babesiosis: active compounds, molecular mechanisms, application limitations and translational development.Frontiers in cellular and infection microbiology · 2026Review
- Article
- Design and screening of novel molecular compounds targeting lactate dehydrogenase of Babesia microti.Parasites & vectors · 2025Article
- Persistent human babesiosis with low-grade parasitemia, challenges for clinical diagnosis and management.Heliyon · 2024Review
- Evaluating Antimalarial Proteasome Inhibitors for Efficacy inACS omega · 2024Article
- Article
- Tafenoquine for Relapsing Babesiosis: A Case Series.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis.The Journal of infectious diseases · 2024Article
- Babesia BdFE1 esterase is required for the anti-parasitic activity of the ACE inhibitor fosinopril.The Journal of biological chemistry · 2023Article
- Transfusion-transmittedJournal of clinical microbiology · 2023Review
- Protective efficacy and correlates of immunity of immunodominant recombinantInfection and immunity · 2023Article
- Article
- Plasma Blood Levels of Tafenoquine following a Single Oral Dosage in BALBc Mice with AcutePathogens (Basel, Switzerland) · 2023Article
- Relapsing Babesiosis With Molecular Evidence of Resistance to Certain Antimicrobials Commonly Used to TreatOpen forum infectious diseases · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Babesiosis treatment failures with standard therapy have been reported, but the molecular mechanisms are not well understood. We describe the emergence of atovaquone and azithromycin resistance associated with mutations in the binding regions of the target proteins of both drugs during treatment of an immunosuppressed patient with relapsing babesiosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.